Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.
|Original language||English (US)|
|Journal||American journal of ophthalmology|
|State||Published - Jul 2007|
Bibliographical noteFunding Information:
This study was supported by an unrestricted grant from Research to Prevent Blindness, New York, New York (Dr Lee), Research Support Schering Plough, Kenilworth, New Jersey (Dr Peereboom), Research Support Genetech, San Francisco, California (Dr Peereboom), and UCB Pharma, Smyrna, Georgia grant support (Dr Stevens). Financial conflict of interest is the same as support. Involved in design and conduct of the study (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); collection (A.G., S.J.F.); management (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); analysis (A.G., A.D.S., S.J.F.); interpretation of the data (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); preparation (A.G., A.D.S., S.J.F.); and review and approval of the manuscript (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.).